Evidence map›Paper›PMID 27942885›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2017

Toxoplasma infection in individuals in central Italy: does a gender-linked risk exist?

B Pinto, R Mattei, G A Moscato, M Cristofano, M Giraldi, R Scarpato, W Buffolano, F Bruschi

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Anti-Pathogens (Basel, Switzerland) · 2023
    Review
  3. Pathogens (Basel, Switzerland) · 2020
    Article
  4. Epidemiologic Survey onPathogens (Basel, Switzerland) · 2020
    Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

B PintoDepartment of Translational Research, New Technologies in Medicine and Surgery (NTMS), Università di Pisa, via Roma, 55-56126, Pisa, Italy. barbara.pinto@dps.unipi.it.ORCID http://orcid.org/0000-0003-2447-7500
R MatteiChemical, Clinical and Microbiological Laboratory, USL Toscana Nord Ovest, Lucca, Italy.
G A MoscatoDepartment of Laboratory Medicine, Pisa University Cisanello Hospital, Pisa, Italy.
M CristofanoMedical Direction, Azienda Ospedaliero, Universitaria Pisana, Pisa, Italy.
M GiraldiMedical Direction, Azienda Ospedaliero, Universitaria Pisana, Pisa, Italy.
R ScarpatoUnit of Genetic & Microbiology, Department of Biology, Università di Pisa, Pisa, Italy.
W BuffolanoDepartment of Pediatrics, University Hospital Federico II, Naples, Italy.
F BruschiDepartment of Translational Research, New Technologies in Medicine and Surgery (NTMS), Università di Pisa, via Roma, 55-56126, Pisa, Italy.
University of Pisa · ITAzienda Ospedaliera Universitaria Pisana · ITAzienda Usl Toscana Centro · ITFederico II University Hospital · ITOspedale Cisanello · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An accurate estimate of the impact of toxoplasmosis on the population in Italy is not available. We performed a cross-sectional study on individuals living in Italy to assess: (1) differences in access to Toxo testing and in the prevalence of recent and past Toxoplasma gondii infection according to gender and age, and (2) the clinical impact of disease burden on the male patient subset. Reason for testing, condition of in- or outpatient and clinical data were analysed. Between-gender differences were observed in access to the test. Immunoglobulin M (IgM) prevalence was increased in males in the age range 5-34 years [odds ratio (OR) = 2.03, 95% confidence interval (CI) 1.18-3.49, p = 0.01), with a peak at 25-34 years. In females, it decreased in the age range 20-39 years (OR = 0.49, 95% CI 0.32-0.74, p = 0.0008). The attack rate of recent infection was twice as high for males than for females. Estimates pointed out 3.3 and 1.7 events in 1000 at-risk person-years in the male and female cohorts, respectively. Most IgM-positive subjects did not experience severe forms of toxoplasmosis, with 35% having lymphadenopathy. Chorioretinitis, systemic and neurological manifestations were also observed. Our findings suggest that the acute phase of toxoplasmosis is largely unapparent or clinically mild in this area. It is also possible that the disease burden for Toxoplasma infection in Italy is underestimated. Further study should focus on information acquisition and Toxo test access in hospital units for a better estimation of the real burden of mild and severe forms of the disease.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, ProtozoanChildChild, PreschoolCross-Sectional StudiesFemaleHealth Services AccessibilityHumansImmunoglobulin MInfantInfant, NewbornItalyMaleAntibodies, ProtozoanImmunoglobulin M

Identifiers

PMID27942885
OpenAlexW2559784476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.